Clinical and Patient-Reported Outcomes of Advanced Urothelial Carcinoma Following Discontinuation of PD-1/L1 Inhibitor Therapy

Alicia K Morgans,Simrun Grewal,Zsolt Hepp,Rupali Fuldeore,Shardul Odak,Cynthia Macahilig,Alicia C Shillington,Guru Sonpavde

Clinical Genitourinary Cancer（2022）

引用 2|浏览2

暂无评分

摘要

•An ambispective chart review of patients with la/mUC following PD-1/L1 therapy.•Following PD-1/L1 inhibitor discontinuation, only one third received subsequent treatment.•OS was longer in patients who received additional therapy following discontinuation of PD-1/L1 inhibitor.•Real-world outcomes in patients with la/mUC following PD-1/L1 therapy are poor.

查看译文

关键词

Bladder cancer,Health-related quality of life,Novel treatment,Survival,Treatment patterns

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要